Clinical Trials Browser

Completed × Hematologic Neoplasms × Lenalidomide × Clear all

NCT01919619 2024-12-03

Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies

Phase 2 Completed

41 enrolled 11 charts

LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Lymphoma, B-Cell, Lymphoma, T-Cell, Hematologic Neoplasms

NCT02843074 2023-12-05

Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients

Phase 2 Completed

53 enrolled 14 charts

Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms

NCT00742560 2018-01-10

A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma

Phase 2 Completed

101 enrolled 20 charts

Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms

NCT01460420 2017-07-06

EMN-alloRIC

Phase 1/2 Completed

Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms

NCT01183663 2016-06-03

Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

Phase 1 Completed

BreastCNSDermatologicGastrointestinalGenitourinaryOther hematologic neoplasmPlasma cell

Breast Neoplasms, Carcinoma, Renal Cell, Colonic Neoplasms, Glioblastoma, Melanoma, Multiple Myeloma, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms